13th Annual Global Embolization Symposium & Technologies
Purpose : The aim of this study was to compare the treatment response and survival profiles between drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres® microspheres (CSM) and conventional transarterial chemoembolization (cTACE) in hepatocellular carcinoma (HCC) patients.
Material and Methods : Three hundred and thirty-five HCC patients receiving DEB-TACE with CSM or cTACE were consecutively enrolled in this multi-center, retrospective cohort study, whom were divided into DEB-TACE group and cTACE group accordingly. Treatment response were assessed by enhanced CT or MRI according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) at month 1 (M1), M3 and M6 after treatment. Progression free survival (PFS) and overall survival (OS) were assessed.
Results : Complete response (CR) at M3 (P=0.020) and objective response rate (ORR) at M1 (P<0.001), M3 (P<0.001) and M6 (P=0.018) were elevated in DEB-TACE group compared with cTACE group. In addition, progression free survival (PFS) (P=0.503) and overall survival (OS) (P=0.203) did not vary between DEB-TACE and cTACE group. DEB-TACE independently correlated with elevated ORR at M1 (P=0.002) and more prolonged OS (P=0.023). In addition, ALP abnormal independently associated with lower ORR at M3, history of drink and largest nodule size ≥7 cm were independent predictive factors for decreased ORR at M6. Largest nodule size ≥7 cm and ALB abnormal were independent predicting factors for shorter PFS, Child-pugh stage B/C, ALB abnormal, ALP abnormal and AFP abnormal were independently associated with unfavorable OS.
Conclusions : DEB-TACE with CSM presents with more favorable treatment response and survival profile compared with cTACE in HCC patients.